COSCIENS Biopharma Inc. (CSCIF) Form 6-K — Jun 22, 2026
COSCIENS Biopharma Inc. announced the approval of a Share Capital Amendment at its annual general meeting, which includes a consolidation of common shares on a 1-for-150 basis followed immediately by a 50-for-1 split. This transaction results in a net reduction of shareholders' pre-consolidation holdings by a factor of three and is expected to become effective on July 3, 2026. Shareholders holding fewer than 150 common shares as of the effective date will receive cash consideration of $1.60 per share, while those with 150 or more shares will receive replacement shares reflecting the new structure.
Key figures
- Split Ratio
- 50:1
- Effective Date
- July 3, 2026
- Consolidation Ratio
- 1:150
- Net Reduction Factor
- 3:1
- Cash Out Price Per Share
- $1.60 USD
- Cash Out Threshold Shares
- 150
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.